CAS: 104-06-3; N-(4-((2-Carbamothioylhydrazono)Methyl)Phenyl)Acetamide

上下游产品

ammonium thi°Cyanate (E)-2-(4-aminobenzylidene)hydrazinecarbothioamide acetic anhydride para-acetamidobenzaldehydeacetic acid-[4-(thiazol-2-ylhydrazono-methyl)-anilide] H-pyrazol-4-yl)-thiazol-2-ylhydrazonomethyl]-anilide}acetic acid-{4-[4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-thiazol-2-ylhydrazonomethyl]-anilide} N,N'''-bis-(4-acetylamino-benzylidene)-μ-disulfido-dicarboxamidrazoneN,N'''-bis-(4-acetylamino-benzylidene)-μ-disulfido-dicarboxamidrazone 1-(4-acetylamino-benzyl)-thiosemicarbazide

📜对乙酰氨基苯甲醛置于肼体系中,化学反应 2.0H,反应生成氨硫脲
参考文献:Preparation Of P-Acetaminobenzaldehyde Thiosemicarbazone
标题:Preparation Of P-Acetaminobenzaldehyde Thiosemicarbazone
摘要:
Doi:10.1021/ja01101A504

专利信息

专利号:US-5157143-A
优先权日:1988-05-11
标题 :Diastereoselective process for the preparation of intermediates useful for the synthesis of peptide derivatives
发明人：PELLACINI FRANCO; CHIARINO DARIO; CARENZI ANGELO
权利人:ZAMBON SPA
摘要:A diastereoselective process for the preparation of compounds of formula ##STR1## (wherein R and R 1 have the meanings reported in the specification and the asterisks show the asymmetric carbon atoms) starting from the corresponding N-protected 2-amino-3-aryl-propan-1-ol is described. n The compounds of formula I are intermediates useful for the synthesis of pharmacologically active peptides.

专利号:US-4902790-A
优先权日:1985-10-10
标 题 :Novel process for the synthesis of amikacin
发明人：MANGIA ALBERTO; GIOBBIO VICENZO; ORNATO GIORGIO
权利人:PIERREL SPA
摘要:A novel process for the synthesis of amikacin starting from kanamycin A protected at the positions 3 and 6' is described comprising the reaction of kanamycin A with a salt of a bivalent metal cation selected from zinc, nickel, iron, cobalt, manganese, copper and cadmium in the presence of water as the solvent or co-solvent followed by the in situ reaction of the resulting complex with a reactive derivative of L-amino-2-hydroxy-butyric acid, removal of the metal cation of the protecting groups and purification of the thus obtained raw product. The acylation under these conditions is extremely selective.

专利号:US-6191290-B1
优先权日:1999-02-24
标 题 :Taxane derivatives for targeted therapy of cancer
发明人：SAFAVY AHMAD
权利人:UAB RESEARCH FOUNDATION
摘要:The present invention describes for the first time the design and synthesis of a soluble tumor-directed paclitaxel prodrug which may establish a new mode of utilization of the taxane class of anticancer agents in cancer therapy.

专利号:US-9890126-B2
优先权日:2012-04-24
标 题:Synthesis of novel inhibitors of isoprenoid biosynthesis (ISPF)
发明人：HAGEN TIMOTHY J; ZHANG ZHENG; LAZOWSKI ZACHARY; CLARE MICHAEL; BEGLEY DARREN W
权利人:UNIV NORTHERN ILLINOIS BOARD OF TRUSTEES; BERYLLIUM DISCOVERY CORP
摘要:Antibacterial and antimalarial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit parasite or bacterial growth.

专利号:US-2022009967-A1
优先权日:2020-07-13
标题 :Isolation and Semi-Synthesis of Rufomycin Analogs
发明人：FRANZBLAU SCOTT G
权利人:UNIV ILLINOIS
摘要:Provided herein are compounds having a structure according to formula I, pharmaceutical compositions thereof, and methods of treating a bacterial infection thereof.

专利号:WO-2024250607-A1
优先权日:2023-06-05
标 题:Chemically modified cytidine triphosphate and preparation method therefor and use thereof
发明人：MEI HUI; DAI ZIWEN; WEN JUNLIN; ZOU YING
权利人:SHENZHEN INST OF ADV TECH CAS
摘要:The present invention provides a chemically modified cytidine triphosphate and a preparation method therefor and a use thereof. According to the present invention, by using a chemical synthesis means, chemically modified cytidine and chemically modified cytidine triphosphate are synthesized, and natural cytidine triphosphate in an mRNA is simply replaced with the chemically modified cytidine triphosphate or is replaced with the combination of the chemically modified cytidine triphosphate and N1-methylpseudouridine triphosphate, so as to enhance the translation efficiency and stability of a target mRNA, reduce immunogenicity, and provide a supplement and new option for mRNA modification technology.